Obsidiantx

3 known investors

Obsidian Therapeutics develops engineered cell and gene therapies, including its lead candidate OBX-115 in advanced melanoma. Its proprietary cytoDRiVE platform uses drug responsive domains (DRDs) to control protein function via an FDA-approved small molecule.